Cisplatin-based chemotherapy in renal transplant recipients: A case report and a review of the literature

Benisovich, Vladimir; Silverman, Lewis R.; Slifkin, Robert F.; Stone, Nelson N.; Cohen, Elliot L.

doi:10.1002/(sici)1097-0142(19960101)77:1<160::aid-cncr26>3.0.co;2-2

Cited by 20 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two RTx recipients with paraaortic lymph node metastasis died 10 and 16 months after diagnosis. There were no cases of chemotherapy‐induced renal failure [18].…”

Section: Discussionmentioning

confidence: 99%

Transitional Cell Carcinoma in Renal Transplant Recipients

Kao

Yang

et al. 2003

World j. surg.

View full text Add to dashboard Cite

Renal transplantation (RTx) recipients have a high incidence of cancer, including transitional cell carcinoma (TCC). Posttransplantation urologic malignancies still present a challenge for transplant surgeons. Using the Dialysis and Transplant Registry of Taichung Veterans General Hospital, a total of 55 cancers were diagnosed in 52 RTx recipients between May 1983 and September 2001. Of these, 24 RTx recipients developing TCC were identified and presented the distinctly high percentage (43.6%) of TCC that were malignancies after RTx in Taiwan. The mean time between transplantation and initial diagnosis was 46 months in our series. Painless hematuria with pyuria is the most common mode of presentation. Transitional cell carcinoma of RTx recipients had multiple foci. Moreover, synchronous TCC in bilateral upper urinary tracts were confirmed in 9 (41%) recipients. The pathologic status of disease is invasive at diagnosis (pTa: 2, pT1: 7, pT2: 4, pT3: 6, pT4: 2, graft metastasis: 1 and distant metastasis: 2). Disseminated metastasis occurred in 6 recipients, all of whom died of their disease within 16 months. Five recipients received adjuvant chemotherapy and retained stable renal function. We conclude that RTx recipients have a markedly increased incidence of TCC in Taiwan, and that prophylactic bilateral nephroureterectomy of native kidneys with bladder cuff excision can be performed simultaneously in RTx recipients with TCC.

show abstract

“…Two RTx recipients with paraaortic lymph node metastasis died 10 and 16 months after diagnosis. There were no cases of chemotherapy‐induced renal failure [18].…”

Section: Discussionmentioning

confidence: 99%

Transitional Cell Carcinoma in Renal Transplant Recipients

Kao

Yang

et al. 2003

World j. surg.

View full text Add to dashboard Cite

show abstract

“…In addition to the standard nephroureterectomy with bladder cuff removal for upper tract TCC, and transurethral rejection (TUR) for superficial bladder tumor, adjuvant systemic or intravesical chemotherapy may also be administered. Although Cisplatin‐based adjuvant systemic chemotherapy in renal transplant recipients is well tolerated together with CsA for immunosuppression, it appears to have only a limited role in treating the rapid progression of TCC in renal transplant recipients (8). In our series, there were three extremely advanced cases of TCC, two stage T3 and one stage T3bN3.…”

Section: Discussionmentioning

confidence: 99%

The outcome of post‐transplant transitional cell carcinoma in 10 renal transplant recipients

Wang

Hsieh

Chen

et al. 2002

Clinical Transplantation

View full text Add to dashboard Cite

At our clinic we followed 320 renal transplant recipients, 16 of whom developed malignancies within 15 yr. Ten of the 16 malignancies were transitional cell carcinoma (TCC) of the urinary tract. The modalities of treatment included standard nephroureterectomy with bladder cuff removal for upper tract tumor, transurethral resection for superficial bladder tumor and partial cystectomy for one case of invasive bladder tumor, as requested by the patient. Post-operative intravesical chemotherapy with epirubicin, or immunotherapy with bacillus Calmette-Guerin (BCG) were carried out for superficial bladder tumor. Cyclosporine (CsA) used as post-transplant immunosuppressant was switched to low dose azathioprine (Aza) at the initial diagnosis of TCC. Four patients experienced tumor recurrence despite conversion of immunosuppressant from CsA to Aza. Among these 10 patients, five maintained normal renal function, three returned to hemodialysis without tumor recurrence, and two patients died of cancer.

show abstract

“…Given the high propensity of nephrotoxicity, cisplatin is contraindicated in preexisting renal impairment, and use in KTRs is limited. One case report suggests that a cisplatin‐based chemotherapy regimen was well tolerated without detriment to allograft function .…”

Section: Chemotherapeuticsmentioning

confidence: 99%

Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients

Krisl

Doan

2017

American Journal of Transplantation

View full text Add to dashboard Cite

It is estimated that solid organ transplant recipients have a two- to fourfold greater overall risk of malignancy than the general population. Some of the most common malignancies after transplant include skin cancers and posttransplant lymphoproliferative disorder. In addition to known risk factors such as environmental exposures, genetics, and infection with oncogenic viruses, immunosuppression plays a large role in the development of cancer through the loss of the immunosurveillance process. The purpose of this article is to explain the role of immunosuppression in cancer and to review the classes of chemotherapeutics. The field of anticancer drugs is continually expanding and developing, with limited data on use in transplant recipients. This article aims to provide information on class review, adverse effects, dose adjustments, and drug interactions that are pertinent to the care of transplant recipients.

show abstract

Cisplatin-based chemotherapy in renal transplant recipients: A case report and a review of the literature

Cited by 20 publications

References 17 publications

Transitional Cell Carcinoma in Renal Transplant Recipients

Transitional Cell Carcinoma in Renal Transplant Recipients

The outcome of post‐transplant transitional cell carcinoma in 10 renal transplant recipients

Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients

Contact Info

Product

Resources

About